What Duojimeike lengthens cancer of terminal liver cell is total live period

With comfort agent group appearance to compare, duojimei (all alone pulls blame Buddhist nun) tablet can lengthen Asia-Pacific area significantly cancer of terminal liver cell (HCC) always live period 47.3% , the disease progress time that also can extend these patients significantly 74% . Data still shows, duojimei is safe to the patient of Asia-Pacific area, can be able to bear or endure suffer, the serious rate that produces undesirable event is low to in degree.

With comfort agent group appearance to compare, duojimei (all alone pulls blame Buddhist nun) tablet can lengthen Asia-Pacific area significantly cancer of terminal liver cell (HCC) always live period 47.3% , the disease progress time that also can extend these patients significantly 74% . Data still shows, duojimei is safe to the patient of Asia-Pacific area, can be able to bear or endure suffer, the serious rate that produces undesirable event is low to in degree.

These data offerred further proof, namely no matter disease characteristic how, no matter cancer of the liver is ill because of how, duojimei is right the patient of cancer of the liver of all sorts of district is effective. And the standard that this makes terminal liver cancer quickly already treats plan, be up to now exclusive patient of liver cancer of an ameliorable Asia always lives period is regnant cure medicaments.

The incidence of a disease of cancer of the liver of Asia-Pacific area grows continuously, because the infection rate of virus of chronic hepatitis B is very high,this is. Although the experiment of Asia-Pacific area is medium those who enter group patient is ill period later, patient health condition is poorer, the occurence rate that the tumour outside liver changes is higher also, consequently overall live period shorter, but group of treatment of much auspicious beauty and contrast group of photograph comparing, its live period lengthen and extent of prolate of disease progress time and the SHARP test result that announced last year agree almost completely.